Overexpression of CCND1 is associated with type II IFN signature in human AML. (A-B) A Kaplan-Meier survival curve for recipient mice that underwent transplantation with 1 × 10⁶ EVI1-AML cells expressing shRNAs against indicated genes, after exposure to 4.5 Gy TBI. The data for shLuciferase are common in Figure 7A-B and supplemental Figure 7E. (C-E) Frequency of cellular subsets of CD4 T (C), CD8 T (D), and CD122⁺ NK (E) cells infiltrating the spleen of EVI1-AML mice with indicated shRNA after exposure to 6.5 Gy TBI. Please see supplemental Figure 6H. (F) qPCR showing the relative expression of Ifng in the spleen T and NK cells from shLuc- or shCcnd1-EVI1-AML mice, used in Figure 6D. (G) qPCR showing the relative expression of chemokines in the EVI1-AML cells 72 hours after transduction of shLuc or shCcnd1. (H) An overall survival of TCGA cohorts according to CCL4 expression divided at 90th percentile. (I) Overall survival of TCGA cohorts according to CCL5 expression divided at 50th percentile. (J) Pearson correlation analysis between CCL4 and CCND1 expression in TCGA samples. (K) Pearson correlation analysis between estimated expression of TIGIT in CD4 T cells calculated using CIBERSORTx and CCND1 expression in TCGA samples. (L-M) Pearson correlation analysis between estimated expression of IFNG in CD8 T cells calculated using CIBERSORTx and MECOM/CCND1 expressions in TCGA samples. (N) Pearson correlation analysis between estimated expression of ICOS in CD8 T cells calculated using CIBERSORTx and CCND1 expression in TCGA samples. (O) Pearson correlation analysis between estimated expression of LAG3 in NK cells calculated using CIBERSORTx and CCND1 expression in TCGA samples. Mean ± SD. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001.